Infant RSV immunoprophylaxis changes nasal epithelial DNA methylation at six years of age

Cheng-Jian Xu, PhD^{1,2,3,4,*}, Nienke M. Scheltema, MD⁵, Cancan Qi, MSC^{6,7}, Rolf Vedder, BSC⁸

Laura B.C. Klein, MD⁵, Elisabeth E. Nibbelke, MSC⁵, Cornelis K van der Ent, MD⁹, Louis J. Bont,

MD^{5,10,#} and Gerard H. Koppelman, MD^{6,7,#}

¹ Centre for Individualised Infection Medicine, CiiM, a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany.

² Research Group of Bioinformatics and Computational Genomics, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Hannover Medical School and the Helmholtz Centre for Infection Research, Hannover, Germany

³ Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

⁴ Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands

⁵ Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands

⁶ Department of Pediatric Pulmonology and Pediatric Allergy, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

⁷ GRIAC research institute Groningen, University of Groningen, University Medical Center Groningen, the Netherlands.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

⁸ University of Groningen, University Medical Center Groningen, Department of Genetics,
Groningen, the Netherlands.

⁹Department of Pediatric Pulmonology, Wilhelmina Children's Hospital, Wilhelmina
Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands.

¹⁰Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, the
Netherlands

These authors contributed equally to this work as joint senior authors

Corresponding author contact information:

Dr. Cheng-Jian Xu

Email: Xu.Chengjian@mh-hannover.de

Centre for individualized infection medicine (CiiM),

Feodor-Lynen-Street 7, 30625 Hannover, Germany

Tel : +49 511 22002 7175

Abstract (200 Words)

Background: Respiratory syncytial virus (RSV) infection has been associated with childhood wheeze and asthma, and potential mechanisms include persistent epigenetic effects.

Methods: In the randomized, placebo-controlled MAKI trial, 429 preterm infants randomly received RSV immunoprophylaxis with palivizumab or placebo during their first RSV season. Children were followed until age 6 for asthma evaluation. DNA methylation in cells obtained by nasal brushes at age 6 was measured by Illumina MethylationEPIC array.

Results: RSV immunoprophylaxis in infancy had significant impact on global methylation patterns in nasal cells at age 6. The first principal component related to the immunoprophylaxis intervention was enriched for the pathway “positive regulation of defense response to virus by host” and “antigen processing and presentation” and driven by methylation changes in *NOD2*, *DGKG*, *MSH3*, and *ITPR2*. Three CpG sites, cg18040241, cg08243963, cg19555973 were differentially methylated at genome-wide significance, but were not associated with asthma. Differential methylation region analysis identified regions near genes that were previously implicated in the development of asthma and allergy such as *HLA-DPA1*, *HLA-DPB1*, *FASLG*, and *CHI3L1*.

Conclusions: The study provides the first proof of concept that RSV immunoprophylaxis during infancy has long-term effects on nasal epigenetic signatures at age 6, relating to host antiviral defense pathways.

Keywords: RSV infection, epigenetics, RSV immunoprophylaxis, DNA methylation, asthma

Background (2190 words)

Human Respiratory syncytial virus (RSV)-related acute lower respiratory tract infection is a leading cause of severe respiratory morbidity and mortality in children [1]. RSV infection in early life is associated with increased risk of early childhood wheezing [2][3][4][5][6].

Recurrent wheezing and asthma are thought to result from alterations in early life immune development following RSV infection, when the immune system is immature. Premature born children are at higher risk for the adverse effects of early life RSV lower respiratory tract infection. However, how RSV infection would have a long-term effect on the host immune system and how this would relate to the development of asthma remains unknown.

Epigenetics refers to (heritable) changes in gene expression that are not encoded by genetic variation. Recent epigenome-wide association studies (EWAS) of allergic diseases have reported encouraging results [7][8][9][10], and epigenetics might explain the high degree of plasticity of the immune response throughout life [11]. For example, in a recent EWAS, we reported 14 CpG methylation sites in whole blood were associated with childhood asthma, that related to distinct gene expression signatures reflecting early life activation of eosinophils and effector/memory CD8 T cells and NK cells at the expense of naïve T cell subsets, providing support for a role of early life antiviral immunity in asthma inception [7]. Indeed, RSV infection may have epigenetic consequences. RSV infection of Dendritic Cells leads to alterations in histone methylation by the H3K4 demethylase KDM5B, resulting in decreased pro-inflammatory cytokine production and a subsequent increase of Th2 cytokines from T cells[12]. Moreover, RSV has been related to a nasal airway microRNA profile which is predicted to have a downregulated NF- κ B signaling pathway [13]. Among these epigenetic markers, DNA methylation provides a stable marker which is suitable for investigating mechanisms for long-term regulation of gene expression upon environmental stimulation [14]. Many studies relate early life exposures to DNA methylation signatures

later in life, yet these observational studies may subject to confounding and causation remains to be verified by future studies. A possible solution to this would be to nest epigenetic analyses in a randomized controlled clinical trial, where the exposure can be controlled by the randomized intervention.

We hypothesized that RSV infection in early life causes changes in DNA methylation in the nasal airway epithelium in childhood. To test this hypothesis, we investigated the randomized clinical trial MAKI [2] (ISRCTN registry, number ISRCTN73641710) to investigate the direct link between RSV prophylaxis during infancy and DNA methylation changes in the nasal epithelium at age 6. In this trial, we observed significant protective effects of early life RSV prophylaxis on having RSV infection and asthma symptoms in the first years of life [2][3]. We performed an epigenome-wide association study (EWAS) to identify differentially methylated patterns in relation to palivizumab prevention at the global, individual and regional CpG site level.

Method

Study design and participants

In the MAKI trial, 429 otherwise healthy late preterm infants were enrolled between 2008 and 2010, and they were born at 33 to 35 weeks of gestation. Infants were randomly assigned to receive palivizumab (n=214) or placebo (n=215) during their first RSV season. Baseline characteristics at randomization are available at NEJM.org[2]. Details about the design, definitions, protocol of the primary study, follow-up study and clinical assessment have been previously described[2][3]. Clinical assessment at age 6 years included questionnaires for respiratory symptoms (parent-reported current asthma) as well as a parent report of a physician's diagnosis of asthma, lung function tests (FEV_{0.5}, FVC), and

assessment of specific IgE to a panel of aeroallergens as well as total serum IgE. Positive specific IgE was defined as an allergen-specific IgE concentration of at least 0.35 kU/L for house dust mite, birch, mugwort, timothy, *Aspergillus fumigatus*, dog, and cat[3].

Nasal DNA methylation measurements

Nasal epithelial cells were collected by nasal brushing around age 6 years of age at a home visit by a trained investigator. Briefly, the right nostril of the subjects was examined and the inferior turbinate was located using a speculum and penlight. The lateral area underneath the inferior turbinate was then brushed for 3 seconds with two brushes (Copan, 56380CS01 FLOQswabs) and these were placed in a 2 ml screw-cap Eppendorf tube and put into a freezer at – 80°C until further processing.

DNA was extracted from nasal brushes using the DNA investigator kit (Qiagen, Benelux BV, Venlo, the Netherlands). This was followed by precipitation-based purification and concentration using GlycoBlue (Ambion). 500 ng of DNA was bisulphite-converted using the EZ 96-DNA methylation kit (Zymo Research), following the manufacturer's standard protocol. After verification of the bisulphite conversion step using Sanger Sequencing, DNA concentration was normalized and the samples were randomized to avoid batch effects. One standard DNA sample per chip was included in this step for quality control. In total, 296 nasal epithelium samples with sufficient DNA quality and quantity were hybridized to the Infinium HumanMethylationEPIC BeadChip array (Illumina, San Diego, CA, USA).

Data pre-processing and statistical analysis

DNA methylation data were pre-processed in R with the Bioconductor package Minfi[15], using the original IDAT files extracted from the HiScanSQ scanner. We implemented sample filtering to remove 6 bad quality samples (call rate <99%) and 16 samples with gender

mismatch. During processing, bad quality probes which failed more than 10% of the samples, the probes on sex chromosomes, the probes that mapped to multiple loci, and the probes containing SNPs at the target CpG sites with a MAF>5% in European populations were excluded¹⁴. We subsequently implemented stratified quantile normalization[17]. To remove the effect of extreme outliers in data, we trimmed the methylation set using: (25th percentile -3*IQR) and (75th percentile+3*IQR), where IQR=interquartile range. In our predefined analysis plan, we followed the trial design by relating the DNA methylation signatures at age 6 years to the palivizumab intervention. The association of DNA methylation with palivizumab intervention was conducted using robust linear regression corrected for sex, age at nasal brush sampling, maternal smoking, batch and surrogate variable analysis (SVA)[18] which represent unknown confounders such as cell type heterogeneity. Principal component analysis (PCA) and nonmetric multidimensional scaling (NMDS)[19] were utilized to check the global effects of palivizumab prophylaxis. R package vegan was used for nonmetric multidimensional scaling analysis (NMDS). Principal components associated with the intervention were analyzed, and the top 20 CpG sites contributing to the first two principal components were annotated using illumina Infinium MethylationEPIC Manifest File (version 1.0), with significant pathways detected by gene network (www.genenetwork.nl)[20]. For single CpG site analysis, adjustment for multiple testing was done using Benjamini & Hochberg method. Significant differentially methylated CpG site were considered when the P-value after False Discovery rate correction (FDR) was less than 0.05. For regional analysis, comb-p[21] was used to identify differentially methylated regions (DMRs) by using the summery statistics from models of single CpG site analysis. All statistical analyses were performed using the computing environment R (version 3.32).

Results

Sample characteristics

Figure 1 illustrated the flow chart of initial enrollment, follow-up and quality control of DNA methylation data in the MAKI study. After quality control, 274 (63.8%) of the collected samples and 790,437 probes remained for further analyses. The baseline characteristics of 274 participating children (132 palivizumab; 142 placebo), representing 63.9 % of the original study population, are presented in Table 1. Median age at the time of nasal brush collection was 6.6 years. Current asthma was defined as parent reported wheeze or asthma medication in the past 12 months[3] ; current allergic asthma was defined as having asthma and specific IgE to aeroallergens at age 6 years. Asthma prevalence was somewhat lower in the palivizumab group compared to the placebo group (14 vs 24%, $P=0.065$) (Table 1), and no differences were observed in lung function ($FEV_{0.5}$) and total serum IgE levels, as reported previously in the full study population[3].

Differential methylation profiling analysis

After QC, 790,437 CpG sites were available for downstream analyses. The principal components analysis (PCA) plot (Figure 2a) and nonmetric multidimensional scaling (NMDS) plot (Figure 3) illustrated an overall methylation difference at age 6 years between the RSV immunoprophylaxis group and placebo group. The first two principal components ($P_{\text{value}_{pc1}}=8.1 \times 10^{-3}$; $P_{\text{value}_{pc2}}=1.0 \times 10^{-2}$) were significantly associated with RSV immunoprophylaxis (Table E1). NMDS confirmed this overall methylation difference between the two groups (adonis, $R^2=0.107$, $P=0.0055$, with 1999 permutations) (Figure 3).

We next performed an Epigenome Wide Association Analysis (EWAS), and three CpG sites (cg18040241, cg08243963 and cg19555973) which are localized in *Galactosidase Beta 1 Like 2 (GLB1L2)* and *SC5DL* (encoding lathosterol oxidase involved in cholesterol biosynthesis) were genome wide significantly associated with RSV immunoprophylaxis versus placebo (Figure 4a, Table E2, $P<0.05$ after FDR correction). These genes have not been previously

implicated in viral immune responses or asthma development. The lambda value was 1.123, which indicated no strong inflation in the model after SVA correction (Figure 4b). In differential methylation region (DMR) analysis, we identified 43 DMRs in relation to RSV immunoprophylaxis (Table E3).

Pathway analysis

To identify pathways explaining these overall methylation differences after RSV immunoprophylaxis, we selected the top 20 CpG sites contributing most to the first two PCs (Table E4 and E5). We next performed pathway analysis by Gene Network[22] on genes located closely to these CpG sites. The pathway analysis of PC1 indicated enrichment of Go biological pathways involved in “positive regulation of defense response to virus by host” driven by *NOD2* (a known innate immunity gene), *DGKG*, *MSH3* and *ITPR2*, and “viral budding via host endosomal sorting complexes required for transport (ESCRT) ” driven by *CANX*, *SEMA4D*, *ITPR2* and *ADK* (Figure 2b, Table E6). Based on gene network clustering, Figure 2c depicts two clusters in this gene network: “positive regulation of interleukin-1 beta secretion” and “antigen processing and presentation of peptide antigen via MHC class I” (Table E7 and E8). The pathway analysis on genes linked to PC2 showed relation to innate immune response genes (Table E9).

Link of RSV prophylaxis epigenetic markers to asthma and allergy

We next related PC1 of RSV immunoprophylaxis associated methylation to patient reported asthma at age 6 years, but did not observe an association (Point-Biserial correlation -0.077, $P=0.20$). The three CpG sites which were associated with RSV immunoprophylaxis were also not associated with patient reported asthma (Table E10). We linked RSV prevention related epigenetic markers to asthma and allergy associated CpG sites at regional level as many well-known asthma and allergy genes have been identified (Table E3). This differential

methylation region analysis identified regions near genes that were previously implicated in the development of asthma and allergy such as *HLA-DPA1*, *HLA-DPB1*, *FASLG*, and *CHI3L1*. [24] We further tested 30 CpG sites which were reported to be associated with allergic asthma from a recent nasal epigenomics study[23], yet none of these were associated with RSV immunoprophylaxis (Table E11). However, we did replicate 16 of these 30 CpG sites associated with allergic asthma in nasal epithelium in our study (Table E12).

Discussion

This work shows that RSV prophylaxis by palivizumab at infancy has global and persistent effects on nasal DNA methylation patterns in childhood. We could observe such changes at global, single CpG site and regional level. Using pathway analysis, we linked these immunoprophylaxis associated global DNA methylation changes to viral response and viral budding genes. We propose that prevention of RSV respiratory tract infection in early childhood leads to different timing and severity of early life RSV respiratory tract infection, which in turn affects local DNA methylation of relevant innate immune response genes. This was further evidenced by differential methylation of cg16834953 in the *NOD2* gene, which functions as a viral pattern recognition receptor and participates in inducing antiviral signaling [24].

An important question is whether the epigenetic patterns we identified would lead to functional differences of these nasal cells, for example in response to other respiratory infections. An alternative explanation would be a direct effect of palivizumab on global gene methylation patterns, or microbiome changes in relation to early life RSV infections that in turn could affect nasal DNA methylation. To our knowledge, this is the first time that long-term methylation effects could be related to the timing of early life RSV infection. We performed our study within the framework of the randomized controlled MAKI trial,

enabling us to infer causality rather than reporting an association, as can be done in observational cohorts. As we expect all children to have had RSV respiratory tract infections at the age of six years, we interpret our findings on changes in palivizumab related DNA methylation as an effect of timing and/or severity of early life RSV infection. However, this hypothesis needs further validation in future studies, focused on the timing and severity of early life RSV infection, preferentially in a longitudinal design. The low prevalence of documented RSV infection in the first year of life did not enable us to perform these analyses in this cohort (see table 1).

We did not identify a direct link between the epigenetic markers associated with RSV immunoprophylaxis and asthma at age 6 years in global and single site analyses, but identified some overlap in regional analysis. Although some asthma genes were identified, there was no strong overlap between the RSV immunoprophylaxis associated gene set and previously published asthma associated CpG sites. This is in line with the clinical findings in this cohort, reporting no strong association with early life palivizumab prevention and doctor's diagnosed asthma at age 6 years[3]. Much larger studies are needed to identify a potential link between RSV immunoprophylaxis, epigenetic changes and asthma[25].

Despite the overall robustness and biological plausibility of our study findings, there are some limitations to consider. Firstly, to the best of our knowledge, there are no suitable data or cohorts available for replication of our findings. The study by O'Brien *et al.*[26] did not include epigenetic studies in the long-term follow up [personal communication]. Second, there is no gold standard to define cell composition in nasal brushes, so we used surrogates variables[18] to represent cell types. Third, our study was single blinded. Fourth, we could not directly confirm that these methylation changes in nasal epithelium regulated gene expression, which should be part of future studies. Fifth, although we studied over 800,00

CpG sites of the human methylome, this still represents about 3 % of all human CpG sites.

Further work confirming these differentially methylated sites and detailed assessment of the associated regions using pyrosequencing should be performed. Sixth, other factors may also associate with DNA methylations, such as age[27], cigarette smoke[28], air pollution[29], or other respiratory infections. However, given that our analysis was embedded in a randomized controlled clinical trial, it is very reasonable to assume that potential confounders are distributed equally across the two treatment arms; and that the results were driven by the RSV Immunoprophylaxis.

In conclusion, infant RSV prophylaxis persistently changes nasal epithelial DNA methylation at least until age 6 years, and these methylation profiles are linked to regulation of anti-viral host defense responses and viral budding process.

Abbreviations

RSV: Respiratory syncytial virus; EWAS: Epigenome-wide association studies; PCA: Principal components analysis; NMDS: Nonmetric multidimensional scaling; DMR: Differential methylation region; ESCRT: Endosomal sorting complexes required for transport.

Acknowledgements

The authors are indebted to all the participating children and their families for their commitment and participation. We thank all members of the MAKI research team, including the staff of the pediatric lung function laboratory, and the laboratory staff. We also thank the staff of the Genomics Analysis Facility for providing technical assistance with the methylation analyses of this study.

Authors' contributions

The study was conceived and designed by LJB and GHK. CJX, CQ and RV performed statistical analyses, CJX drafted the manuscript and interpreted the data. NMS, LJB and GHK contributed to the manuscript writing. NMS, LBCK, EEN, CK and LJB obtained informed consent and clinical information. All authors reviewed and provided comments to the final manuscript (CJX, NMS, CQ, RV, LBCK, EEN, CK, LJB, GHK). All authors read and approved the final manuscript.

Availability of data and materials

The epigenetic datasets generated and analyzed are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The MAKI trial was approved by the ethical committee Medisch Ethische Toetsingscommissie (METC) of the Universitair Medisch Centrum Utrecht(21/07/2008) , and all study participants provided written consent.

Funding

This study was supported by MedImmune grant ESR-14-10006

Potential conflict of interest:

This study was supported by a grant from MedImmune to LJB and GHK. Funders had no role in design, interpretation and reporting of this study. L.J.B. reports grants from AbbVie during the conduct of the study and grants from MedImmune, Janssen, MeMed, and the Bill & Melinda Gates Foundation. None of the other authors report competing interests relating to the work presented in this manuscript.

References

1. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, Alassani I, Ali A, Antonio M, Awasthi S, Awori JO, Azziz-Baumgartner E, Baggett HC, Baillie VL, Balmaseda A, Barahona A, Basnet S, Bassat Q, Basualdo W, Bigogo G, Bont L, Breiman RF, Brooks WA, Broor S, Bruce N, Bruden D, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *The Lancet* 2017; 390: 946–958.
2. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JLL, Bont L. Respiratory Syncytial Virus and Recurrent Wheeze in Healthy Preterm Infants. *N. Engl. J. Med.* 2013; 368: 1791–1799.
3. Scheltema NM, Nibbelke EE, Pouw J, Blanken MO, Rovers MM, Naaktgeboren CA, Mazur NI, Wildenbeest JG, van der Ent CK, Bont LJ. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. *Lancet Respir. Med.* 2018; 6: 257–264.
4. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. *Am. J. Respir. Crit. Care Med.* 2000; 161: 1501–1507.
5. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *The Lancet* 1999; 354: 541–545.
6. Rosas-Salazar C, Shilts MH, Tovchigrechko A, Schobel S, Chappell JD, Larkin EK, Gebretsadik T, Halpin RA, Nelson KE, Moore ML, Anderson LJ, Peebles RS, Das SR, Hartert TV. Nasopharyngeal Lactobacillus is associated with a reduced risk of childhood wheezing illnesses following acute respiratory syncytial virus infection in infancy. *J. Allergy Clin. Immunol.* 2018; 142: 1447-1456.e9.
7. Xu C-J, Söderhäll C, Bustamante M, Baiz N, Gruziova O, Gehring U, Mason D, Chatzi L, Basterrechea M, Llop S, Torrent M, Forastiere F, Fantini MP, Carlsen KCL, Haahtela T, Morin A, Kerkhof M, Merid SK, Rijkom B van, Jankipersadsing SA, Bonder MJ, Ballereau S, Vermeulen CJ, Aguirre-Gamboa R, Jongste JC de, Smit HA, Kumar A, Pershagen G, Guerra S, Garcia-Aymerich J, et al. DNA methylation in childhood asthma: an epigenome-wide meta-analysis. *Lancet Respir. Med.* 2018; 6: 379–388.
8. Liang L, Willis-Owen SAG, Laprise C, Wong KCC, Davies GA, Hudson TJ, Binia A, Hopkin JM, Yang IV, Grundberg E, Busche S, Hudson M, Rönnblom L, Pastinen TM, Schwartz DA, Lathrop GM, Moffatt MF, Cookson WOCM. An epigenome-wide association study of total serum immunoglobulin E concentration. *Nature* 2015; 520: 670–674.
9. Reese SE, Xu C-J, den Dekker HT, Lee MK, Sikdar S, Ruiz-Arenas C, Merid SK, Rezwan FI, Page CM, Ullema V, Melton PE, Oh SS, Yang IV, Burrows K, Söderhäll C, Jima DD, Gao L, Arathimos R, Küpers LK, Wielscher M, Rzehak P, Lahti J, Laprise C, Madore A-M, Ward J, Bennett BD, Wang T, Bell DA, Vonk JM, Håberg SE, et al. Epigenome-wide

- meta-analysis of DNA methylation and childhood asthma. *J. Allergy Clin. Immunol.* 2019; 143: 2062–2074.
10. Peng C, Cardenas A, Rifas-Shiman SL, Hivert M-F, Gold DR, Platts-Mills TA, Lin X, Oken E, Avila L, Celedón JC, Weiss ST, Baccarelli AA, Litonjua AA, DeMeo DL. Epigenetic age acceleration is associated with allergy and asthma in children in Project Viva. *J. Allergy Clin. Immunol.* 2019; 143: 2263–2270.e14.
 11. Tost J. A translational perspective on epigenetics in allergic diseases. *J. Allergy Clin. Immunol.* 2018; 142: 715–726.
 12. Ptaschinski C, Mukherjee S, Moore ML, Albert M, Helin K, Kunkel SL, Lukacs NW. RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis In Vivo. *PLOS Pathog.* 2015; 11: e1004978.
 13. Hasegawa K, Pérez-Losada M, Hoptay CE, Epstein S, Mansbach JM, Teach SJ, Piedra PA, Camargo CA, Freishtat RJ. RSV vs. rhinovirus bronchiolitis: difference in nasal airway microRNA profiles and NFκB signaling. *Pediatr. Res.* 2018; 83: 606–614.
 14. Chen R, Xia L, Tu K, Duan M, Kukurba K, Li-Pook-Than J, Xie D, Snyder M. Longitudinal personal DNA methylome dynamics in a human with a chronic condition. *Nat. Med.* 2018; : 1.
 15. Fortin J-P, Triche J Timothy J, Hansen KD. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. *Bioinformatics* 2017; 33: 558–560.
 16. McCartney DL, Walker RM, Morris SW, McIntosh AM, Porteous DJ, Evans KL. Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. *Genomics Data* 2016; 9: 22–24.
 17. Touleimat N, Tost J. Complete pipeline for Infinium® Human Methylation 450K BeadChip data processing using subset quantile normalization for accurate DNA methylation estimation. *Epigenomics* 2012; 4: 325–341.
 18. Leek JT, Storey JD. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis. *PLOS Genet.* 2007; 3: e161.
 19. Kenkel NC, Orloci L. Applying Metric and Nonmetric Multidimensional Scaling to Ecological Studies: Some New Results. *Ecology* 1986; 67: 919–928.
 20. Deelen P, van Dam S, Herkert JC, Karjalainen JM, Brugge H, Abbott KM, van Diemen CC, van der Zwaag PA, Gerkes EH, Zonneveld-Huijssoon E, Boer-Bergsma JJ, Folkertsma P, Gillett T, van der Velde KJ, Kanninga R, van den Akker PC, Jan SZ, Hoorntje ET, te Rijdt WP, Vos YJ, Jongbloed JDH, van Ravenswaaij-Arts CMA, Sinke R, Sikkema-Raddatz B, Kerstjens-Frederikse WS, Swertz MA, Franke L. Improving the diagnostic yield of exome-sequencing by predicting gene–phenotype associations using large-scale gene expression analysis. *Nat. Commun.* 2019; 10: 2837.
 21. Pedersen BS, Schwartz DA, Yang IV, Kechris KJ. Comb-p: software for combining, analyzing, grouping and correcting spatially correlated P-values. *Bioinformatics* 2012; 28: 2986–2988.

22. Fehrmann RSN, Karjalainen JM, Krajewska M, Westra H-J, Maloney D, Simeonov A, Pers TH, Hirschhorn JN, Jansen RC, Schultes EA, van Haagen HHHBM, de Vries EGE, te Meerman GJ, Wijmenga C, van Vugt MATM, Franke L. Gene expression analysis identifies global gene dosage sensitivity in cancer. *Nat. Genet.* 2015; 47: 115.
23. Forno E, Wang T, Qi C, Yan Q, Xu C-J, Boutaoui N, Han Y-Y, Weeks DE, Jiang Y, Rosser F, Vonk JM, Brouwer S, Acosta-Perez E, Colón-Semidey A, Alvarez M, Canino G, Koppelman GH, Chen W, Celedón JC. DNA methylation in nasal epithelium, atopy, and atopic asthma in children: a genome-wide study. *Lancet Respir. Med.* 2019; 7: 336–346.
24. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, Dube PH, Xiang Y, Bose S. Activation of innate immune antiviral responses by Nod2. *Nat. Immunol.* 2009; 10: 1073–1080.
25. Riddell CA, Bhat N, Bont LJ, Dupont WD, Feikin DR, Fell DB, Gebretsadik T, Hartert TV, Hutcheon JA, Karron RA, Nair H, Reiner RC, Shi T, Sly PD, Stein RT, Wu P, Zar HJ, Ortiz JR. Informing randomized clinical trials of respiratory syncytial virus vaccination during pregnancy to prevent recurrent childhood wheezing: A sample size analysis. *Vaccine* 2018; 36: 8100–8109.
26. O’Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. *Lancet Infect. Dis.* 2015; 15: 1398–1408.
27. Xu C-J, Bonder MJ, Söderhäll C, Bustamante M, Baiz N, Gehring U, Jankipersadsing SA, van der Vlies P, van Diemen CC, van Rijkom B, others. The emerging landscape of dynamic DNA methylation in early childhood. *BMC Genomics* 2017; 18: 25.
28. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, Reese SE, Markunas CA, Richmond RC, Xu C-J, Küpers LK, Oh SS, Hoyo C, Gruziova O, Söderhäll C, Salas LA, Baiz N, Zhang H, Lepeule J, Ruiz C, Ligthart S, Wang T, Taylor JA, Duijts L, Sharp GC, Jankipersadsing SA, Nilsen RM, Vaez A, Fallin MD, Hu D, et al. DNA Methylation in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-analysis. *Am. J. Hum. Genet.* 2016; 98: 680–696.
29. Gruziova O, Xu C-J, Breton CV, Annesi-Maesano I, Antó JM, Auffray C, Ballereau S, Bellander T, Bousquet J, Bustamante M, Charles M-A, de Kluizenaar Y, den Dekker HT, Duijts L, Felix JF, Gehring U, Guxens M, Jaddoe VVW, Jankipersadsing SA, Merid SK, Kere J, Kumar A, Lemonnier N, Lepeule J, Nystad W, Page CM, Panasevich S, Postma D, Slama R, Sunyer J, et al. Epigenome-Wide Meta-Analysis of Methylation in Children Related to Prenatal NO₂ Air Pollution Exposure. *Environ. Health Perspect.* 2017; 125: 104–110.

Figure Captions

Figure 1. Flow chart of enrollment at age 0, follow up at age 6, and quality control of DNA methylation data in MAKI study.

Figure 2. Principal component analysis (PCA) of global methylation patterns. **A**, PCA plot of global methylation patterns in DNA obtained nasal epithelial brushing in relation to Palivizumab intervention. Two PCs were significantly associated with the intervention: PC1 ($p=8.1 \times 10^{-3}$) and PC2 ($p=1.0 \times 10^{-2}$). **B**, Gene set analysis of PC1 using Go-biological process databases. **C**, Gene network of genes that significantly contribute to PC1. These genes annotate to immune related genes that were differentially methylated after RSV immunoprophylaxis in the first year of life. There are two clusters (blue and green) in this network.

Figure 3: Non metric dimensional biplot. NMDS biplots depicting the individual overall methylation levels (data points, $n=274$), colored by treatment group: placebo (blue, $n=132$) and Palivizumab (red, $n=142$). The difference in overall methylation levels is significant (adonis, $R^2=0.0195$, P value= 0.0115, with 1999 permutation a) NMDS1- NMDS2 b) NMDS1- NMDS3.

Figure 4. a) Manhattan plot of 790,437 CpG sites for differentially methylation with early life RSV prophylaxis by palivizumab. P values (y axis) correspond to the significance of the difference in methylation between prevention and no prevention subject. The red line correspond to the P value $FDR=0.05$ threshold. b) A quantile-quantile (QQ) plot displays the experimentally observed P values (vertical axis) as well as the expected P values of a null distribution (horizontal axis). The observed p value is obtained from the association between CpG sites methylation and RSV prophylaxis. The model to test the association is methylation $\sim$ RSV prophylaxis + age at nasal brush sample + sex + maternal smoking + batch, without correction of surrogate variables. The grey area represents the 95% concentration band.

Table 1 Sample characteristics from MAKI methylation study

	Palivizumab	Placebo	P-value
Sample size	132	142	
Age of phenotyping (years)*	5.79 (0.20)	5.84 (0.28)	0.098
Age of nasal brush sampling (years)	6.61 (0.39)	6.65 (0.41)	0.397
Male sex, n (%)	84 (63.6)	69 (48.6)	0.017
Asthma , n (%)	19 (14.4)	34 (23.9)	0.065
FEV ₀₅ (mean(sd))	89.51 (9.61)	90.06 (11.49)	0.68
Total IgE (mean (sd))	148.70 (290.87)	134.23 (177.47)	0.692
Total RSV infection (%)	7 (5.3)	22 (15.8)	0.01
Medically attended RSV infection (%)	2 (1.5)	13 (9.4)	0.011
RSV infection without medical attention (%)	5 (3.8)	9 (6.6)	0.461

Abbreviation: Fev₀₅ (Forced Expiratory volume in 0.5s). IgE (Immunoglobuline E).

Missing values were not included. P-values for categorical variables were calculated using χ^2 test comparing the palivizumab group and placebo group, and continuous variables by t-test.

* the age of phenotyping of asthma, FEV₀₅ and Total IgE.

Fig. 1

Fig. 2

Fig. 3

Table E1 The association of the first ten principal components with Infant RSV immunoprophylaxis.

Principal components	Associated p value*
PC1	8.11×10^{-3}
PC2	1.04×10^{-2}
PC3	2.94×10^{-1}
PC4	9.99×10^{-1}
PC5	8.44×10^{-1}
PC6	7.08×10^{-2}
PC7	7.25×10^{-1}
PC8	7.42×10^{-1}
PC9	2.00×10^{-1}
PC10	9.82×10^{-1}

Legend to Table E1: * Association was investigated with logistic regression model to test the association of RSV immunoprophylaxis ~ principal components).

Table E2 Associations between DNA methylation and RSV immunoprophylaxis with adjustment for surrogate variables.

Cpgsite	Chr	Position	Beta	P-value	P_adjust	Genelist
cg18040241	11	134201582	0.55	6.62×10^{-9}	5.23×10^{-3}	<i>GLB1L2</i>
cg08243963	11	121163095	0.38	8.62×10^{-8}	3.41×10^{-2}	<i>SC5DL</i>
cg19555973	20	31866225	0.38	1.72×10^{-7}	4.54×10^{-2}	<i>NA</i>
cg13191195	1	181382847	-0.19	1.17×10^{-6}	1.65×10^{-1}	<i>NA</i>
cg01715450	1	14609119	-0.13	1.22×10^{-6}	1.65×10^{-1}	<i>NA</i>
cg16457505	18	48249020	-0.15	1.25×10^{-6}	1.65×10^{-1}	<i>MAPK4</i>
cg12017117	9	90271285	-0.16	1.59×10^{-6}	1.70×10^{-1}	<i>DAPK1</i>
cg09295021	7	148393388	-0.15	1.72×10^{-6}	1.71×10^{-1}	<i>NA</i>
cg22791543	5	127416532	0.13	2.10×10^{-6}	1.71×10^{-1}	<i>FLJ33630</i>
cg26148106	21	47472200	-0.15	2.23×10^{-6}	1.71×10^{-1}	<i>NA</i>

Legend to table E2: Sites in bold are genome wide significant after correction for multiple testing.

Table E3 DMRs associated with RSV immunoprophylaxis at an SLK-Sidak P value of less than 0.05.

Chr	Start	End	Num	slk_sidak_p	Gene	Location
15	81426347	81426821	9	2.30×10^{-10}	<i>CFAP161</i>	TSS+intron+utr5+cds
6	29894050	29894254	8	1.19×10^{-7}	<i>HCG4B</i>	nc_exon
6	33048254	33048920	19	1.31×10^{-7}	<i>HLA-DPA1;HLA-DPB1</i>	TSS+intron+exon+utr5;intron+cds
11	117069780	117070047	8	8.87×10^{-6}	<i>TAGLN;LOC100652768</i>	TSS+exon+utr5;nc_intron
11	94278324	94278604	7	2.59×10^{-5}	<i>LOC105369438;FUT4</i>	nc_exon;cds
1	17614144	17614281	2	3.82×10^{-5}	<i>PADI3</i>	intergenic
1	203155884	203156626	6	4.59×10^{-5}	<i>CHI3L1</i>	intergenic
11	128812804	128813009	8	4.66×10^{-5}	<i>TP53AIP1</i>	exon+utr5
19	55660514	55660871	7	5.52×10^{-5}	<i>TNNT1</i>	TSS+intron+exon+utr5
17	79881468	79881544	5	8.07×10^{-5}	<i>MAFG</i>	intron+utr5
17	79297435	79297707	4	2.23×10^{-4}	<i>LINC00482</i>	intergenic
2	7171869	7172098	6	2.75×10^{-4}	<i>RNF144A</i>	intron
6	29911265	29911559	5	5.82×10^{-4}	<i>HLA-A</i>	intron+cds
2	121498194	121498813	3	6.26×10^{-4}	<i>GLI2</i>	intergenic
12	89748726	89749081	8	7.97×10^{-4}	<i>DUSP6</i>	intergenic
8	74282708	74282932	4	1.44×10^{-3}	<i>RDH10-AS1</i>	intergenic
12	122019006	122019118	6	1.92×10^{-3}	<i>KDM2B</i>	intergenic
12	130976379	130976552	3	1.94×10^{-3}	<i>RIMBP2</i>	intron+utr5
5	172751061	172751409	5	2.32×10^{-3}	<i>STC2</i>	intron
10	135342413	135342937	3	2.50×10^{-3}	<i>CYP2E1</i>	intron
7	105319558	105319820	5	4.04×10^{-3}	<i>ATXN7L1</i>	TSS+exon+utr5;intron
1	172608566	172608705	3	4.32×10^{-3}	<i>FASLG</i>	intergenic
1	59042931	59043256	7	4.36×10^{-3}	<i>TACSTD2</i>	TSS+exon
17	38498816	38499097	4	5.99×10^{-3}	<i>RARA;RARA-AS1;RARA</i>	intron;nc_intron+nc_exon;utr5+cds
4	681086	681155	3	6.77×10^{-3}	<i>SLC49A3</i>	intron
2	6072744	6072982	6	7.83×10^{-3}	<i>SILC1</i>	nc_exon
9	96715047	96715257	2	8.39×10^{-3}	<i>BARX1</i>	intron+cds
6	30079139	30079281	8	9.66×10^{-3}	<i>TRIM31-AS1;TRIM31;TRIM31</i>	nc_intron;nc_intron;intron
8	120685124	120685318	4	1.01×10^{-2}	<i>ENPP2</i>	intron
16	70780647	70780948	4	1.24×10^{-2}	<i>VAC14</i>	intron
7	157368881	157369159	6	1.55×10^{-2}	<i>PTPRN2</i>	intron
19	15530606	15530871	4	2.28×10^{-2}	<i>AKAP8L</i>	intergenic

7	4228775	4228949	2	2.42×10^{-2}	<i>SDK1</i>	intron
22	29470209	29470348	4	3.35×10^{-2}	<i>KREMEN1</i>	intron
6	31166502	31166800	4	3.48×10^{-2}	<i>HCG27</i>	nc_intron
21	43735722	43735936	6	3.50×10^{-2}	<i>TFF3</i>	intergenic
19	1155030	1155226	4	3.53×10^{-2}	<i>SBNO2</i>	intron+utr5
10	31146954	31147089	2	3.82×10^{-2}	<i>ZNF438</i>	intron;intron+utr5; nc_intron
3	52877048	52877272	3	4.04×10^{-2}	<i>STIMATE;STIMATE-MUSTN1</i>	intron;intron
6	15401024	15401068	3	4.17×10^{-2}	<i>JARID2</i>	intron;intron+utr5
1	108235664	108235771	2	4.24×10^{-2}	<i>VAV3</i>	intron
9	117692745	117693072	7	4.56×10^{-2}	<i>TNFSF8</i>	TSS+exon+utr5
22	36500566	36500794	3	4.81×10^{-2}	<i>APOL3</i>	intergenic

Legend to Table E3:

Chr: Chromosome

Start: start position of the region

End: end position of the region

Num: number of probes in the region

Sidak p-value: adjusted p value by comb-p method

Table E4 The top 20 CpG sites that contributed most in loadings to the first principal component (PC1).

Cpgsite	Chr	Position	Genelist	Group	Relation to Cpgisland	Loadings
cg16401111	9	92015016	<i>SEMA4D</i>	Body	OpenSea	6.04×10^{-3}
cg05757496	15	91272726	<i>BLM</i>	5'UTR	OpenSea	6.01×10^{-3}
cg01937742	9	92016748	<i>SEMA4D</i>	Body	OpenSea	5.95×10^{-3}
cg20877250	5	179136518	<i>CANX</i>	Body	OpenSea	5.90×10^{-3}
cg04349497	5	80162419	<i>MSH3</i>	Body	OpenSea	5.89×10^{-3}
cg06043346	3	186048659	<i>DGKG</i>	5'UTR	OpenSea	5.88×10^{-3}
cg16958035	10	89866320			OpenSea	5.87×10^{-3}
cg16834953	16	50748861	<i>NOD2</i>	Body	OpenSea	5.87×10^{-3}
cg17649852	12	26613608	<i>ITPR2</i>	Body	OpenSea	5.86×10^{-3}
cg00191409	12	65093708			OpenSea	5.85×10^{-3}
cg01239499	7	30210587			OpenSea	5.85×10^{-3}
cg02822894	2	105940459	<i>TGFBPAP1</i>	5'UTR	OpenSea	5.85×10^{-3}
cg11304191	8	95874874	<i>INTS8</i>	Body	OpenSea	5.83×10^{-3}

cg15340456	5	140961838	<i>DIAPH1</i>	Body	OpenSea	5.82×10^{-3}
cg00182040	6	14337524			OpenSea	5.81×10^{-3}
cg04868129	5	82673283			OpenSea	5.80×10^{-3}
cg01809361	2	28823246	<i>PLB1</i>	Body	OpenSea	5.79×10^{-3}
cg10009801	6	30168645	<i>TRIM26</i>	5'UTR	OpenSea	5.79×10^{-3}
cg06032386	10	75926796	<i>ADK</i>	Body	OpenSea	5.79×10^{-3}
cg10140227	11	116852379	<i>SIK3</i>	Body;5'UTR	OpenSea	5.79×10^{-3}

Table E5 The top 20 CpGs that contributed most in loadings to the first principal component (PC2).

Cpgsite	Chr	Position	Genelist	Group	Relation to Cpg Island	Loadings
cg01697719	22	19754125	<i>TBX1</i>	Body	Island	7.15×10^{-3}
cg08382235	22	19754251	<i>TBX1</i>	Body	Island	6.78×10^{-3}
cg13332774	10	106028628	<i>GSTO2</i>	TSS200	Island	6.62×10^{-3}
cg22413388	22	46367617	<i>WNT7B</i>	Body	Island	6.62×10^{-3}
cg17121176	6	107956004	<i>SOBP</i>	Body	Island	6.23×10^{-3}
cg10332422	13	114292552	<i>TFDP1</i>	Body	Island	5.62×10^{-3}
cg10927841	2	26407743	<i>FAM59B</i>	Body	Island	5.55×10^{-3}
cg24477102	8	2879917	<i>CSMD1</i>	Body	Island	5.53×10^{-3}
cg25389087	18	74824413	<i>MBP</i>	5'UTR	Island	5.51×10^{-3}
cg18456523	5	54516805			Island	5.51×10^{-3}
cg10448954	16	89593394	<i>SPG7</i>	Body	Island	5.36×10^{-3}
cg15894683	20	56805751			S_Shore	5.34×10^{-3}
cg19563510	17	79881483	<i>MAFG</i>	5'UTR;TSS200	S_Shore	5.34×10^{-3}
cg11875917	8	4980497			Island	5.31×10^{-3}
cg26900073	12	132276572	<i>SFSWAP</i>	Body	Island	5.31×10^{-3}
cg15271348	13	114292740	<i>TFDP1</i>	Body	Island	5.29×10^{-3}
cg02833580	12	65996465	<i>LOC100507065</i>	Body	OpenSea	-5.35×10^{-3}
cg03577157	5	80716263	<i>RNU510;S</i> <i>SBP2</i>	Body;3'UTR	OpenSea	-5.45×10^{-3}
cg23282852	6	52255402	<i>PAQR8</i>	5'UTR	OpenSea	-5.47×10^{-3}
ch.22.909671F	22	46114168	<i>ATXN10</i>	Body	OpenSea	-5.76×10^{-3}

Table E6: Gene set analysis of PC1 using Go-Biological process databases.

Gene_set_id	Gene_set_name	P-value
GO:0002230	positive regulation of defense response to virus by host	2.74×10^{-5}
GO:0036258	multivesicular body assembly	3.13×10^{-5}
GO:0039702	viral budding via host ESCRT complex	5.64×10^{-5}
GO:0009653	anatomical structure morphogenesis	8.77×10^{-5}
GO:0035567	non-canonical Wnt signaling pathway	1.66×10^{-4}
GO:1904903	ESCRT III complex disassembly	1.94×10^{-4}
GO:0001523	retinoid metabolic process	3.52×10^{-4}
GO:0016032	viral process	3.62×10^{-4}
GO:0006897	endocytosis	3.80×10^{-4}
GO:0018105	peptidyl-serine phosphorylation	3.92×10^{-4}

Table E7: Gene set analysis by using Go-Biological process databases of green cluster of Figure 2c.

Gene_set_id	Gene_set_name	P-value
GO:0001523	retinoid metabolic process	1.86×10^{-4}
GO:0050718	positive regulation of interleukin-1 beta secretion	4.06×10^{-4}
GO:0042073	intracellular transport	4.23×10^{-4}
GO:0006027	glycosaminoglycan catabolic process	4.35×10^{-4}
GO:0009653	anatomical structure morphogenesis	5.55×10^{-4}
GO:0001657	ureteric bud development	1.06×10^{-3}
GO:0002230	positive regulation of defense response to virus by host	1.40×10^{-3}
GO:0035666	TRIF-dependent toll-like receptor signaling pathway	1.62×10^{-3}
GO:0031640	killing of cells of other organism	1.97×10^{-3}
GO:0018105	peptidyl-serine phosphorylation	1.99×10^{-3}

Table E8: Gene set analysis by using Go-Biological process databases of blue cluster of Figure 2c.

Gene_set_id	Gene_set_name	P-value
GO:0006491	N-glycan processing	2.09×10^{-5}
GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	4.51×10^{-5}
GO:0036258	multivesicular body assembly	2.19×10^{-4}
GO:0034975	protein folding in endoplasmic reticulum	2.82×10^{-4}
GO:0048008	platelet-derived growth factor receptor signaling pathway	2.90×10^{-4}
GO:0007064	mitotic sister chromatid cohesion	3.79×10^{-4}
GO:0006665	sphingolipid metabolic process	3.79×10^{-4}
GO:0006626	protein targeting to mitochondrion	4.22×10^{-4}
GO:0039702	viral budding via host ESCRT complex	5.46×10^{-4}
GO:0006699	bile acid biosynthetic process	6.33×10^{-4}

Table E9: Gene set analysis of PC2 by using Go-Biological process databases.

Gene_set_id	Gene_set_name	P-value
GO:0061077	chaperone-mediated protein folding	3.92×10^{-4}
GO:0099132	ATP hydrolysis coupled cation transmembrane transport	5.77×10^{-4}
GO:0045087	innate immune response	1.61×10^{-4}
GO:0002224	toll-like receptor signaling pathway	1.79×10^{-3}
GO:0030317	flagellated sperm motility	1.87×10^{-3}
GO:0042340	keratan sulfate catabolic process	2.29×10^{-3}
GO:0045893	positive regulation of transcription, DNA-templated	2.45×10^{-3}
GO:0071577	zinc II ion transmembrane transport	3.55×10^{-3}
GO:0042752	regulation of circadian rhythm	3.74×10^{-3}
GO:0050829	defense response to Gram-negative bacterium	4.15×10^{-3}

Table E10: Associations between 3 CpG sites associated with RSV immunoprophylaxis with patient reported asthma.

Cpgsite	Chr	Position	Effect	P-value	Genelist
cg18040241	11	134201582	-0.40	0.08	<i>GLB1L2</i>
cg08243963	11	121163095	-0.024	0.94	<i>SC5DL</i>
cg19555973	20	31866225	-0.097	0.73	NA

Table E11: Associations between 30 CpG sites, which are reported to associate with allergic asthma in a previous study (Forno et al) with RSV immunoprophylaxis.

CpG	Gene	Chr	Position	Effect-discovery	Coef	P-value
cg07239613	<i>CES4A</i>	16	67051005	-4.83	0.05	0.07
cg00664723	<i>FBXL7</i>	5	15927184	-1.81	-0.06	0.08
cg01870976	<i>PCSK6</i>	15	101887154	-1.79	0.05	0.19
cg04132353	<i>CAPN14</i>	2	31440349	-1.91	0.04	0.27
cg20790648	<i>SUCNR1</i>	3	151619923	-1.87	0.05	0.27
cg24707200	<i>NTRK1</i>	1	156833163	-4.91	-0.02	0.32
cg22855021	<i>TSHR</i>	14	81610812	-1.63	0.05	0.33
cg10549071	<i>SPP2</i>	2	235160451	-2.3	0.03	0.37
cg10099207	<i>C15orf54</i>	15	39544144	-1.4	-0.05	0.40
cg01859321	<i>PLEC</i>	8	144970195	-1.45	0.03	0.45
cg15006973	<i>GJA4</i>	1	35258933	-2.86	-0.02	0.48
cg06675531	<i>SYNPO</i>	5	150019123	-4.4	-0.02	0.52
cg09472600	<i>NCF2</i>	1	183537770	-1.65	0.03	0.55
cg21158502	<i>ANKRD31</i>	5	74348187	-2.16	-0.02	0.55
cg16518142	<i>CDH26</i>	20	58533713	-2.89	-0.01	0.61
cg18749617	<i>PCSK6</i>	15	102028637	-1.49	-0.01	0.68
cg13586696	<i>C22orf31</i>	22	29458723	-1.63	-0.02	0.71
cg13570892	<i>DUOX1</i>	15	45449437	-1.61	0.02	0.71
cg22862094	<i>EFNA5</i>	5	106859865	-2.07	-0.01	0.71
cg16027132	<i>CDHR3</i>	7	105521116	-1.6	0.01	0.76
cg19497511	<i>LRRFIP1</i>	2	238609807	-3.44	-0.01	0.76
cg08175352	<i>ZPLD1</i>	3	101894206	-1.72	-0.02	0.78
cg00406211	<i>GRK5</i>	10	121077022	-2	0.01	0.78
cg17223698	<i>C15orf54</i>	15	39416631	-3.31	0.00	0.88
cg19610615	<i>ADCK1</i>	14	78446340	-1.6	0.00	0.90
cg20372759	<i>METTL1</i>	12	58162287	-1.97	0.00	0.91
cg03387497	<i>BANF2</i>	20	17680945	-1.88	0.00	0.97
cg03875819	<i>LINC00704</i>	10	4386802	-1.65	0.00	0.98
cg10830021	<i>NUP98</i>	11	3815589	-1.5	0.00	0.99
cg08844313	<i>PDE6A</i>	5	149240529	-1.92	NA	NA

Legend to table E12: 30 CpGs were selected from supplementary Table 7 from Forno E, et al. DNA methylation in nasal epithelium, atopy, and atopic asthma in children: a genome-wide study. *Lancet Respir Med* 2018; DOI:10.1016/S2213-2600(18)30466-1.

Table E12: Associations between 30 CpG sites, which are reported to associate with allergic asthma with allergic asthma in MAKI data and 16 out of 29 could be replicated (P value<0.05).

CpG	Gene	Chr	Position	Effect-discovery*	Effect-Maki	P-value
cg20372759	<i>METTL1</i>	12	58162287	-1.97	-6.10	3.53 ×10⁻⁴
cg15006973	<i>GJA4</i>	1	35258933	-2.86	-5.99	3.82 ×10⁻⁴
cg24707200	<i>NTRK1</i>	1	156833163	-4.91	-6.78	1.22 ×10⁻³
cg09472600	<i>NCF2</i>	1	183537770	-2.16	-2.84	1.80 ×10⁻³
cg10830021	<i>NUP98</i>	11	3815589	-1.5	-4.94	2.27 ×10⁻³
cg22855021	<i>TSHR</i>	14	81610812	-1.63	-2.03	5.16 ×10⁻³
cg10549071	<i>SPP2</i>	2	235160451	-2.3	-2.93	6.27 ×10⁻³
cg10099207	<i>C15orf54</i>	15	39544144	-1.4	-2.01	1.16 ×10⁻²
cg08175352	<i>ZPLD1</i>	3	101894206	-1.72	-2.26	1.43 ×10⁻²
cg20790648	<i>SUCNR1</i>	3	151619923	-1.87	-2.12	1.53 ×10⁻²
cg00664723	<i>FBXL7</i>	5	15927184	-1.81	-3.48	1.56 ×10⁻²
cg16518142	<i>CDH26</i>	20	58533713	-2.89	-4.49	1.67 ×10⁻²
cg18749617	<i>PCSK6</i>	15	102028637	-1.49	-2.30	2.31 ×10⁻²
cg01870976	<i>PCSK6</i>	15	101887154	-1.79	-2.33	3.26 ×10⁻²
cg00406211	<i>GRK5</i>	10	121077022	-2	-2.92	4.26 ×10⁻²
cg19497511	<i>LRRFIP1</i>	2	238609807	-3.44	-3.41	4.81 ×10⁻²
cg17223698	<i>C15orf54</i>	15	39416631	-1.6	-1.98	5.01 ×10 ⁻²
cg19610615	<i>ADCK1</i>	14	78446340	-3.31	-2.37	5.45 ×10 ⁻²
cg22862094	<i>EFNA5</i>	5	106859865	-2.07	-1.58	6.33 ×10 ⁻²
cg03875819	<i>LINC00704</i>	10	4386802	-1.65	-1.37	1.73 ×10 ⁻¹
cg03387497	<i>BANF2</i>	20	17680945	-1.88	-1.49	1.73 ×10 ⁻¹
cg21158502	<i>ANKRD31</i>	5	74348187	-1.65	-1.02	2.28 ×10 ⁻¹
cg13586696	<i>C22orf31</i>	22	29458723	-1.63	-1.24	2.31 ×10 ⁻¹
cg01859321	<i>PLEC</i>	8	144970195	-1.45	-1.00	2.71 ×10 ⁻¹
cg16027132	<i>CDHR3</i>	7	105521116	-1.6	-0.78	4.06 ×10 ⁻¹
cg13570892	<i>DUOX1</i>	15	45449437	-1.61	-0.53	5.02 ×10 ⁻¹
cg06675531	<i>SYNPO</i>	5	150019123	-4.4	-0.80	5.98 ×10 ⁻¹
cg04132353	<i>CAPN14</i>	2	31440349	-1.91	-0.34	7.10 ×10 ⁻¹
cg07239613	<i>CES4A</i>	16	67051005	-4.83	0.07	9.51 ×10 ⁻¹
cg08844313	<i>PDE6A</i>	5	149240529	-1.92	NA	NA

Legend to table E12: 30 CpGs were selected from supplementary Table 7 from Forno E, *et al.* DNA methylation in nasal epithelium, atopy, and atopic asthma in children: a genome-wide study. *Lancet Respir Med* 2018; DOI:10.1016/S2213-2600(18)30466-1. Sites in bold are P-value <0.05. * Effect discovery is from Forno et al paper.